Page last updated: 2024-09-05

lapatinib and pd 98059

lapatinib has been researched along with pd 98059 in 2 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(pd 98059)
Trials
(pd 98059)
Recent Studies (post-2010) (pd 98059)
1,9193051,4424,93931,001

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)pd 98059 (IC50)
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)2.8
Luciferin 4-monooxygenasePhotinus pyralis (common eastern firefly)6.3
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)2.8
Prostaglandin G/H synthase 1Homo sapiens (human)1
Mitogen-activated protein kinase 1Homo sapiens (human)2.8
Dual specificity mitogen-activated protein kinase kinase 2 Rattus norvegicus (Norway rat)4.2
Dual specificity mitogen-activated protein kinase kinase 1 Rattus norvegicus (Norway rat)4.2
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)2.4

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP1
Crews, LA; Gonzales, T; Kouznetsova, VL; Masliah, E; Overk, CR; Patrick, C; Paulino, A; Price, D; Rockenstein, E; Stocking, E; Tsigelny, IF; Wrasidlo, W1

Other Studies

2 other study(ies) available for lapatinib and pd 98059

ArticleYear
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
    Journal of immunology (Baltimore, Md. : 1950), 2013, Dec-15, Volume: 191, Issue:12

    Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin

2013
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
    British journal of pharmacology, 2014, Volume: 171, Issue:24

    Topics: AIDS Dementia Complex; Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 5; Dasatinib; Erlotinib Hydrochloride; Flavonoids; HIV Envelope Protein gp120; In Vitro Techniques; Indoles; Lapatinib; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Rats; Roscovitine; Sunitinib; Thiazoles

2014